EU imposes guarantees for Illumina-Grail deal during review



By Matthew Perlman (Oct 29, 2021, 4:47 p.m. EDT) – European competition authority demands monitor and threatening fines to ensure Illumina and Grail maintain separation while authorities conduct a review of the reacquisition of $ 8 billion from cancer by DNA sequencing company. -test outfit.

The European Commission said in a statement on Friday that it had imposed so-called interim measures on Illumina and Grail, the first time it has taken such a step on reaching a deal while its merger review is underway. Classes.

Illumina and Grail finalized the decision on Aug. 18, despite an ongoing challenge from U.S. officials in addition to scrutiny in Europe, saying they would keep …

Stay one step ahead

In the legal profession, information is the key to success. You need to know what’s going on with customers, competitors, practice areas, and industries. Law360 provides the intelligence you need to stay an expert and beat the competition.

  • Access to case data in articles (numbers, filings, courts, nature of prosecution, etc.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, requests, etc.
  • Create personalized alerts for specific case articles and topics and more!



Leave A Reply

Your email address will not be published.